Clearmind Medicine Inc. (NASDAQ:CMND) Sees Significant Decrease in Short Interest

Clearmind Medicine Inc. (NASDAQ:CMND) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totaling 88,087 shares, a decline of 56.7% from the June 30th total of 203,361 shares. Based on an average daily trading volume, of 1,322,969 shares, the days-to-cover ratio is currently 0.1 days. Currently, 8.6% of the company’s shares are sold short.

Insider Buying and Selling at Clearmind Medicine

In other Clearmind Medicine news, major shareholder Financial Lp Hrt sold 22,139 shares of Clearmind Medicine stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $3.31, for a total value of $73,280.09. Following the completion of the transaction, the insider directly owned 81,353 shares of the company’s stock, valued at $269,278.43. The trade was a 21.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 252,615 shares of company stock valued at $117,933 over the last ninety days.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Clearmind Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 20th.

Clearmind Medicine Price Performance

Clearmind Medicine stock opened at $1.61 on Monday. Clearmind Medicine has a 1-year low of $1.61 and a 1-year high of $524.00. The stock has a market cap of $1.64 million, a PE ratio of -0.01 and a beta of 0.74. The stock’s fifty day moving average is $2.59 and its two-hundred day moving average is $9.34.

Clearmind Medicine (NASDAQ:CMND) last released its quarterly earnings data on Monday, June 15th. The company reported ($6.78) earnings per share (EPS) for the quarter.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.